

Interim period January - June 2023

- Net asset value was SEK 236.4 per share compared to SEK 196.3 at the beginning of the year, which corresponds to an increase of 20.4 per cent.
- Bure's net asset value was SEK 17,531M compared to SEK 14,559M at the beginning of the year.
- Total return on the Bure share was 2.6 per cent compared to the SIX Return Index which rose 11.3 per cent.
- Group earnings after tax amounted to SEK 3,150M (-9,202). Earnings per share amounted to SEK 42.4 (-124.2).

Interim period April - June 2023

- Net asset value was SEK 236.4 per share compared to SEK 228.8 at the start of the quarter, corresponding to an increase of 3.3 per cent.
- On 19 April 2023, the merger of ACQ Bure AB and Yubico AB was announced. Extraordinary general meetings of ACQ and Yubico on 20 June 2023 decided to approve the merger of the two companies. The planned merger is expected to be approved by the Swedish Companies Registration Office in September 2023 after which trade in the merged company's shares will start on the Nasdaq First Growth Market. Following the merger between ACQ and Yubico, Bure's holding in the merged company, which will change name to Yubico, will amount to 17.4 per cent. For further details, please see www.acq.se.
- In accordance with the annual general meeting's decision, an ordinary dividend of SEK 2.25 per share was paid, totalling SEK 166.8M.

Events after the end of the period

- Net asset value amounted to SEK 204.5 per share on 17 August 2023, corresponding to an increase of 4.2 per cent since the beginning of the year.
- Bure Growth acquired shares in BioLamina for SEK 62M. The shareholding in BioLamina was revalued by SEK 353M.

Henrik Blomquist

CEO Bure Equity AB



The most significant event of the quarter was the deal to merge ACQ and Yubico, which was announced in April. Yubico is a cybersecurity company that is the market leader in multi-factor authentication. The company's proprietary product – YubiKey – protects against the theft of login details, which is one of the single greatest data security threats. The transaction values Yubico at USD 800 million and ACQ shareholders will acquire approximately 40 per cent of the company. Following the transaction, Bure will be the largest owner of the company with a holding of around 17.4 per cent. Yubico will become Bure's third largest holding.

At an extraordinary general meeting in June, ACQ's shareholders voted for the merger and now only registration with the Swedish Companies Registration Office remains, which is expected to take place in mid-September. The goal of having the acquisition company ACQ has thus been achieved and through the merger with Yubico a highly qualitative technology and growth company will be listed on the Swedish stock exchange. It is extremely gratifying and satisfying for me to be able to complete this project after about two years' intensive work and analysing potential target companies – a statement of strength for Bure's organisation and ability to execute.

In conjunction with the publication of ACQ's "last" interim report, Yubico published its first interim report. The business continues to perform strongly. Sales increased 16.2 per cent in local currencies and operating profit was SEK 101 million, corresponding to an EBIT margin of 22.2 per cent.

Other portfolio companies also performed well in the second quarter. Xvivo reported strong organic growth of 46 per cent. In contrast, growth in Vitrolife fell to 4 per cent, which was below market expectations. Growth remained strong in Europe and Asia/Pacific, while a market adjustment in Genetic Services had a negative impact on activity in America. In summary, Bure's net asset value per share increased 3.3 per cent for the quarter, compared to the SIX Return Index, which increased 2.4 per cent in the same period.

Bure's net asset value and holdings

| | | | 2022/12/31 | | | | | 2023/06/3 | 0 |
|---------------------------------|--|--------------|-------------------|------------------------|---------------------|----------|-------------------|----------------------------|--------------------------------------|
| SEK I | М | % of capital | Net asset value | Value change. (+/-) 1) | Investment | Disposal | Net asset value | % of net asset value | Net asset value per share, SEK |
| | ACQ Bure ³⁾ | 20.0% | 718 | 38 | _ | _ | 756 | 4.3% | 10.2 |
| | Cavotec ⁴⁾ | 35.3% | 450 | -10 | 58 | -2 | 496 | 2.8% | 6.7 |
| L 2) | Mentice | 14.7% | 142 | -1 | _ | _ | 141 | 0.8% | 1.9 |
| 10 | Mycronic | 26.9% | 5,153 | 1,874 | _ | _ | 7,027 | 40.1% | 94.8 |
| S T | Ovzon ⁵⁾ | 12.5% | 338 | -217 | 50 | _ | 170 | 1.0% | 2.3 |
| E | Vitrolife | 15.9% | 4,005 | 499 | _ | _ | 4,504 | 25.7% | 60.7 |
| D | Xvivo Perfusion | 14.6% | 799 | 526 | _ | _ | 1,326 | 7.6% | 17.9 |
| | Total listed holdings | | 11,605 | 2,708 | 108 | -2 | 14,420 | 82.3% | 194.5 |
| | | | | | | | | | |
| U | Allgon 6) | 92.6% | 753 | 218 | _ | _ | 971 | 5.5% | 13.1 |
| N L | Atle Investment Management 7) | 93.0% | 256 | _ | 64 | _ | 320 | 1.8% | 4.3 |
| 1.0 | Bure Growth 8) | 100.0% | 1,362 | 61 | 37 | _ | 1,460 | 8.3% | 19.7 |
| S T | Mercuri International 9) | 90.4% | 68 | _ | _ | _ | 68 | 0.4% | 0.9 |
| E D | Total unlisted holdings | | 2,438 | 279 | 101 | 0 | 2,819 | 16.1% | 38.0 |
| | Total holdings | | 14,044 | 2,987 | 209 | -2 | 17,238 | 98.3% | 232.5 |
| T R E A S U R | Cash and cash equivalents, short-term investments and other assets ¹⁰) Total treasury | | 515 515 | | -222 -222 | | 293 293 | 1.7% 1.7% | 3.9 |
| | Total net asset value | | 14,559 | 2,987 | -13 | -2 | 17,531 | 100.0% | 236.4 |

¹⁾ Change in value including exit gains/losses.

Ovzon 6,984,629, Vitrolife 21,510,257 and Xvivo Perfusion 4,367,504. Bure also has 4,200,000 warrants in ACQ Bure.

²⁾ Bure's number of shares at 30 June 2023: ACQ Bure 7,000,000, Cavotec 37,554,921, Mentice 3,761,659, Mycronic 26,317,163,

³⁾ Refers to the valuation of stocks and warrants in ACQ Bure.

⁴⁾ Bure subscribed to 4,408,302 shares in Cavotec's rights issue for SEK 58M. Bure divested 175,000 shares to members of the Cavotec management team.

⁵⁾ Bure subscribed to 1,123,595 shares in Ovzon's rights issue for SEK 50M.

⁶⁾ Bure's direct and indirect holding in Allgon amounts to 92.4 per cent. The holding was revalued by SEK 218M.

⁷⁾ Atle made a conditional shareholder contribution to Atle Investment Services of SEK 8M. Atle paid an additional purchase price for Atle Investment Services and HealthInvest Partners of SEK 60M.

⁸⁾ Bure Growth subscribed to 80,934 shares in ScandiNova Systems rights issue for SEK 36M. The holding in ScandiNova Systems was revalued by SEK 61M.

⁹⁾ Fair value of equity and interest-bearing receivables.

¹⁰⁾ Cash and cash equivalents, participations in funds and short-term investments in market-listed assets, other unlisted companies, interest-bearing receivables and other net assets.

Change in net asset value during 2023



Listed portfolio companies

Listed portfolio companies accounted for 82.3 per cent of net asset value compared to 79.7 per cent at the end of 2022. The total value of listed portfolio companies decreased SEK 2,814M to SEK 14,420M.

Value changes

Value changes due to fluctuations in share prices and exits during the period was SEK 2,708M.

Value changes in SEK M and share price performance 2023

| Total | 2,708 | |
|------------------------------|-------|--------|
| Ovzon | -217 | -57.6% |
| Cavotec | -10 | -2.2% |
| Mentice | -1 | -0.8% |
| ACQ Bure (shares + warrants) | 38 | 3.9% |
| Vitrolife | 499 | 12.5% |
| Xvivo Perfusion | 526 | 65.8% |
| Mycronic | 1,874 | 36.4% |

Bure's comparison index, the SIX RX, rose 11.3 per cent.

Acquisitions

Bure subscribed to shares for SEK 58M in Cavotec's rights issue.

Bure subscribed to shares for SEK 50M in Ovzon's rights issue.

Divestments

Bure divested 175,000 shares in Cavotec for SEK 2M to members of the Cavotec management team.

Dividends received

Bure received share dividends of SEK 110M from Mycronic and Vitrolife.

Unlisted portfolio companies

Unlisted portfolio companies accounted for 16.1 per cent of net asset value compared to 16.7 per cent at the end of 2022.

The value of unlisted portfolio companies decreased SEK 380M to SEK 2,819M.

Acquisitions and value changes

Atle paid an additional purchase price for Atle Investment Services and HealthInvest Partners of SEK 60M.

Atle made a conditional shareholder contribution to Atle Investment Services of SEK 8M.

Bure Growth subscribed to shares in ScandiNova Systems' rights issue for SEK 36M. The holding in ScandiNova Systems was revalued by SEK 61M.

The holding in Allgon was revalued by SEK 218M.

Dividends received

Atle Investment Management received dividends of SEK 62M from the part-owned asset management companies. Bure Growth received dividends of SEK 18M from Allgon.

Treasury

The value of assets in Treasury increased SEK 222M to SEK 393M. During the period, Bure acquired financial assets for SEK 214M and divested financial assets for SEK 2M. Bure paid dividends of SEK 167M. The group received dividends of SEK 172M. Other changes amounting to SEK 16M were due to changes in working capital, value changes in short-term investments and administrative costs.

Assets in Treasury amounted to 1.7 per cent of net asset value compared to 3.5 per cent at the end of 2022.

The Bure share

The total number of Bure shares amounts to 74,252,057, of which 74,146,921 are outstanding. The Bure Annual General Meeting (AGM) of 3 May 2023 authorised the Bure Board of Directors to decide on the buyback of up to 10 per cent of the total number of ordinary shares in Bure Equity AB. Bure did not repurchase any ordinary shares in 2023, nor does it hold any own ordinary shares.

With the backing of an authorisation from the AGM of 3 May 2022, Bure carried out a rights issue and then immediately repurchased 105,136 class C shares. The shares were issued and repurchased in accordance with the LTIP 2022 incentive programme which was adopted by the AGM on 3 May 2022.

| | 17 Aug 2023 | 30 Jun 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|----------------|----------------|----------------|----------------|
| Share price, SEK | 204.4 | 250.6 | 246.4 | 438.2 |
| Dividend per share, SEK | 2.25 | 2.25 | 2.25 | 2.0 |
| Total return since year-end ¹⁾ | -16.3% | 2.6% | -43.1% | 50.1% |
| Net asset value per share, SEK | 204.5 | 236.4 | 196.3 | 323.2 |
| Development of NAV per share | 4.2% | 20.4% | -39.2% | 34.9% |
| SIX Return Index | 6.2% | 11.3% | -22.8% | 39.3% |

¹⁾ Including dividends of SEK 2.25 per share for 2023 and 2022 and SEK 2.00 per share for 2021.

Development of Bure's net asset value and share price per share



| Portfolio companies Jan – | Jun 2023 and 2022 | | |
|------------------------------|-------------------|--------------|---------|
| Listed SEK M | Net sales | 2023 | 2022 |
| | EBIT | -7 | 0 -5 |
| ACQ | EBIT margin | | n/m |
| BURE ACQUISITION | | 20.0% | 20.0% |
| | Holding Net sales | 966 | 619 |
| | EBIT | 17 | -25 |
| CAVOTEC* | | 1.7% | -4.1% |
| | EBIT margin | 35.3% | 35.4% |
| | Holding Net sales | 139 | 98 |
| | EBIT | 5 | -23 |
| mentice | | 3.5% | -23.7% |
| | EBIT margin | 14.7% | 14.7% |
| | Holding Net sales | | |
| | EBIT | 2,464 352 | 2,408 |
| MYCRONIC | | | |
| | EBIT margin | 14.3% | 17.8% |
| | Holding | 26.9% | 26.9% |
| | Net sales | n/a | 178 |
| Ovzon | EBIT | n/a | -26 |
| 0 1 2 0 1 . | EBIT margin | n/a | -14.8% |
| | Holding | 12.5% | 11.4% |
| | Net sales | 1,759 | 1,581 |
| VITROLIFE GROUP [™] | EBIT | 347 | 308 |
| | EBIT margin | 19.7% | 19.5% |
| | Holding | 15.9% | 15.9% |
| | Net sales | 295 | 187 |
| XVIVO | EBIT | 15 | 9 |
| | EBIT margin | 5.1% | 4.7% |
| | Holding | 14.6% | 14.8% |
| Unlisted SEK M | | 2023 | 2022 |
| Omisted SER W | Net sales | 359 | 312 |
| | EBIT | 64 | 49 |
| ALLGON [®] | EBIT margin | 17.7% | 15.6% |
| | Holding | 92.6% | 92.4% |
| | Net sales | 0 | 0 |
| _ | EBIT | 59 | 128 |
| atle | EBIT margin | n/m | n/m |
| 313. 3 | | | |
| | Holding | 93.0% | 93.0% |
| | Net sales | 0 | 0 |
| BURE | EBIT | 59 | 46 |
| SKOWIII | EBIT margin | n/m | n/m |
| | Holding | 100% | 100.0% |
| | Net sales | 171 | 161 |
| MERCURI international | EBIT | 6 | 1 |
| | EBIT margin | 3.4% | 0.7% |

Holding

90.4%

90.4%

Listed portfolio companies



Share of Bure's net asset value: 4.3%

ACQ Bure is a Swedish acquisition company. ACQ's strategy is to identify and conduct the acquisition of a company that can create value for shareholders over time.

| Key figure SEK m | Q2 2023 | Q2 2022 | 6 mth 2023 | 6 mth 2022 | 2022 |
|--------------------------------------|------------|------------|---------------|---------------|-------|
| Net sales | 0 | 0 | 0 | 0 | 0 |
| Operating expenses | -43 | -2 | -45 | -5 | -15 |
| EBIT | -43 | -2 | -45 | -5 | -15 |
| EBIT margin | n/m | n/m | n/m | n/m | n/m |
| Net financial items | 27 | 0 | 38 | 0 | 15 |
| Profit/loss before tax | -16 | -2 | -7 | -5 | -1 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 |
| Profit/loss for the period | -16 | -2 | -7 | -5 | -1 |
| | | | | | |
| Net loan debt (-)/ receivable (+) | | | 3,425 | 3,436 | 3,426 |
| Total assets | | | 3,457 | 3,436 | 3,441 |
| Equity | | | 3,432 | 3,435 | 3,439 |
| Cash flow from operating activities | | | -1 | -6 | -16 |
| Average no. of employees | | | 0 | 0 | 0 |

| Facts at 30 June 2023 | Largest shareholders | | | |
|-------------------------------|------------------------|-------|--|--|
| NAV: SEK 756M ¹⁾ | Bure Equity | 20.0% | | |
| Acquisition date: 2021 | AMF Tjänstepension & | | | |
| Board member from Bure: | Fonder | 20.0% | | |
| Patrik Tigerschiöld, chairman | SEB Fonder & Stiftelse | 11.7% | | |
| Sarah McPhee, board member | Others | 48.3% | | |

¹⁾ Relates to shares and warrants in ACQ Bure.

The quarter in brief

- On 19 April 2023, the merger of ACQ Bure AB and Yubico AB was announced. Extraordinary general meetings of ACQ Bure and Yubico on 20 June 2023 decided to approve the merger of the two companies.
- The planned merger is expected to be approved by the Swedish Companies Registration Office in September 2023 after which trade in the merged company's shares will start on the Nasdaq First Growth Market.
- Following the merger between ACQ and Yubico, Bure's holding in the merged company, which will change name to Yubico, will amount to 17.4 per cent. For further details, please see www.acq.se.
- Yubico's interim report for the period January June 2023 is available at www.acq.se/investerare/fusion.
- The share price increased by 2.9 per cent during the second quarter of 2023.



www.cavotec.com

Share of Bure's net asset value: 2.8%

Cavotec is a leading engineering group that designs and manufactures automated connection and electrification systems for ports and industrial applications worldwide.

| Key figure EUR m | Q2 2023 | Q2 2022 | 6 mth 2023 | 6 mth 2022 | 2022 |
|--|------------|------------|---------------|---------------|-------|
| Net sales | 46 | 32 | 85 | 59 | 148 |
| Operating expenses | -45 | -33 | -84 | -61 | -152 |
| EBIT | 1 | -1 | 1 | -2 | -5 |
| EBIT margin | 2.6% | -3.0% | 1.7% | -4.1% | -3.0% |
| Net financial items | -1 | 3 | -2 | 4 | -1 |
| Profit/loss before tax | 0 | 2 | 0 | 1 | 0 |
| Income tax expense | -1 | 0 | -2 | 0 | -3 |
| Profit/loss for the period continuing operations | -1 | 2 | -2 | 1 | -3 |
| Profit/loss for the period discontinued operations | - | -1 | - | -5 | -11 |
| Profit/loss for the period | -1 | 1 | -2 | -3 | -14 |
| | | | | | |
| Net loan debt (-)/ receivable (+) | | | -23 | -24 | -30 |
| Total assets | | | 158 | 188 | 168 |
| Equity | | | 55 | 59 | 44 |
| Cash flow from operating activities | | | -7 | 2 | 21 |
| Average no. of employees | | | 625 | 616 | 640 |

| Facts at 30 June 2023 | Largest shareholders | |
|-------------------------------|----------------------|-------|
| NAV: SEK 496M | Bure Equity | 35.3% |
| Acquisition date: 2014 | Thomas von Koch | 17.5% |
| Board member from Bure: | Others | 47.2% |
| Patrik Tigerschiöld, chairman | | |

- Order book at the end of the period was EUR 140M (153).
- Net sales increased 44 per cent to EUR 46M (32).
- Operating profit was EUR 1M (-1).
- The share price increased 1.5 per cent during the second quarter of 2023.



www.mentice.com

Share of Bure's net asset value: 0.8%

Mentice develops and sells turn-key simulation solutions targeting the fast-growing market for endovascular procedures.

| Key figure SEK m | Q2 2023 | Q2 2022 | 6 mth 2023 | 6 mth 2022 | 2022 |
|--------------------------------------|------------|------------|---------------|---------------|--------|
| Net sales | 74 | 45 | 139 | 98 | 218 |
| Operating expenses | -69 | -62 | -134 | -121 | -242 |
| EBIT | 5 | -17 | 5 | -23 | -24 |
| EBIT margin | 6.5% | -38.2% | 3.5% | -23.7% | -11.0% |
| Net financial items | 0 | 0 | -1 | 0 | 0 |
| Profit/loss before tax | 5 | -17 | 4 | -24 | -24 |
| Income tax expense | -3 | -1 | -4 | -1 | -7 |
| Profit/loss for the period | 1 | -18 | 0 | -25 | -31 |
| | | | | | |
| Net loan debt (-)/ receivable (+) | | | 22 | 17 | 31 |
| Total assets | | | 310 | 319 | 333 |
| Equity | | | 164 | 170 | 163 |
| Cash flow from operating activities | | | 3 | -7 | 15 |
| Average no. of employees | | | 115 | 117 | 122 |

| Facts at 30 June 2023 | Largest shareholders | |
|---------------------------------|------------------------|-------|
| NAV: SEK 141M | Karin Howell-Bidermann | 34.0% |
| Acquisition date: 2019 | Bure Equity | 14.7% |
| Board member from Bure: | Fjärde AP-fonden | 6.9% |
| Gösta Johannesson, board member | Others | 44.4% |

The quarter in brief

- Order book was SEK 77M (57), corresponding to an increase of 35 per cent. Order book at the end of the period was SEK 125M (109).
- Net sales were SEK 74M (45), an increase of 65 per cent of which 54 per cent was organic.
- Operating profit was SEK 5M (-17).
- The share price increased 1.4 per cent during the second quarter of 2023.

MYCRONIC

www.mycronic.com

Share of Bure's net asset value: 40.1%

Mycronic creates world-leading production equipment for electronics and display manufacturing.

| Key figure SEK m | Q2 2023 | Q2 2022 | 6 mth 2023 | 6 mth 2022 | 2022 |
|--------------------------------------|------------|------------|---------------|---------------|--------|
| Net sales | 1,245 | 1,273 | 2,464 | 2,408 | 5,119 |
| Operating expenses | -1,075 | -1,049 | -2,112 | -1,979 | -4,225 |
| EBIT | 170 | 224 | 352 | 429 | 894 |
| EBIT margin | 13.7% | 17.6% | 14.3% | 17.8% | 17.5% |
| Net financial items | 4 | -2 | 7 | -3 | -4 |
| Profit/loss before tax | 174 | 222 | 359 | 426 | 890 |
| Income tax expense | -41 | -48 | -77 | -88 | -154 |
| Profit/loss for the period | 134 | 174 | 282 | 338 | 737 |
| | | | | | |
| Net loan debt (-)/ receivable (+) | | | 1,395 | 505 | 1,004 |
| Total assets | | | 7,633 | 6,637 | 7,340 |
| Equity | | | 4,663 | 4,214 | 4,703 |
| Cash flow from operating activities | | | 834 | 246 | 853 |
| Average no. of employees | | | 2,026 | 1,969 | 2,002 |

| Facts at 30 June 2023 | Largest shareholders | | | |
|--|----------------------|-------|--|--|
| NAV: SEK 7,027M | Bure Equity | 26.9% | | |
| Acquisition date: 2010 via | SEB Fonder | 10.0% | | |
| Skanditek | Fjärde AP-fonden | 8.5% | | |
| Board member from Bure: Patrik Tigerschiöld, chairman | Others | 54.6% | | |

- Order book was SEK 1,748M (1,203), an increase of 45 per cent, driven by strong performance in Pattern Generators. The combined order book at the end of the period was SEK 4,475M (2,146).
- Net sales decreased 2 per cent to SEK 1,245M (1,273).
- Operating profit amounted to SEK 170M (224), corresponding to an operating margin of 13.7 per cent (17.6). The results reflected the writing off of a development project of approximately SEK 60M.
- The share price increased 4.8 per cent during the second quarter of 2023.

Ovzon

www.ovzon.com

Share of Bure's net asset value: 1.0%

Ovzon offers a revolutionary mobile broadband service via satellite that combines high data speeds with high degrees of mobility.

| Key figure ¹⁾ SEK m | Q2 2023 | Q2 2022 | 6 mth 2023 | 6 mth 2022 | 2022 |
|--------------------------------------|------------|------------|---------------|---------------|--------|
| Net sales | n/a | 78 | n/a | 178 | 357 |
| Operating expenses | n/a | -87 | n/a | -204 | -438 |
| EBIT | n/a | -9 | n/a | -26 | -81 |
| EBIT margin | n/a | -11.3% | n/a | -14.8% | -22.7% |
| Net financial items | n/a | 25 | n/a | 31 | 45 |
| Profit/loss before tax | n/a | 16 | n/a | 5 | -36 |
| Income tax expense | n/a | 0 | n/a | 0 | 0 |
| Profit/loss for the period | n/a | 16 | n/a | 4 | -36 |
| | | | | | |
| Net loan debt (-)/ receivable (+) | | | n/a | -79 | -202 |
| Total assets | | | n/a | 1,967 | 1,922 |
| Equity | | | n/a | 1,436 | 1,393 |
| Cash flow from operating activities | | | n/a | -82 | -112 |
| Average no. of employees | | | n/a | 40 | 43 |

1) Ovzon's interim report is published on 18 August 2023.

| Facts at 30 June 2023 | Largest shareholders | |
|-----------------------------------|-----------------------|-------|
| NAV: SEK 170M | Bure Equity | 12.5% |
| Acquisition date: 2018 | Investment AB Öresund | 12.1% |
| Board member from Bure: | Grignolino AB | 11.3% |
| Patrik Tigerschiöld, board member | Others | 64.1% |

The quarter in brief

- Ovzon received an order from the Italian fire and rescue service for the company's SATCOM-as-a-Service solution through its new partner Vodafone Italia. The eight-month contract period started in May 2023.
- Delays to the building of the Ovzon 3 satellite resulted in its launch being rescheduled to the end of 2023 or beginning of 2024.
- The share price decreased 35.4 per cent during the second quarter of 2023.

VITROLIFE GROUP™

www.vitrolife.com

Share of Bure's net asset value: 25.7%

Vitrolife is an international medtech group that develops, produces, and markets fertility treatment products.

| Key figure SEK m | Q2 2023 | Q2 2022 | 6 mth 2023 | 6 mth 2022 | 2022 |
|--------------------------------------|------------|------------|---------------|---------------|--------|
| Net sales | 905 | 829 | 1,759 | 1,581 | 3,234 |
| Operating expenses | -717 | -654 | -1,412 | -1,273 | -2,580 |
| EBIT | 188 | 175 | 347 | 308 | 654 |
| EBIT margin | 20.8% | 21.1% | 19.7% | 19.5% | 20.2% |
| Net financial items | -53 | -6 | -82 | -26 | -117 |
| Profit/loss before tax | 135 | 169 | 265 | 283 | 537 |
| Income tax expense | -29 | -39 | -60 | -70 | -143 |
| Profit/loss for the period | 106 | 130 | 205 | 213 | 394 |
| | | | | | |
| Net loan debt (-)/ receivable (+) | | | -1,587 | -1,899 | -1,563 |
| Total assets | | | 21,648 | 19,907 | 20,551 |
| Equity | | | 17,679 | 15,991 | 16,740 |
| Cash flow from operating activities | | | 372 | 270 | 636 |
| Average no. of employees | | | 1,079 | 1,147 | 1,117 |

| Facts at 30 June 2023 | Largest shareholders | |
|---|---------------------------|-------|
| NAV: SEK 4,504M | William Demant Invest A/S | 28.7% |
| Acquisition date: 2010 | Bure Equity | 15.9% |
| via Skanditek | Swedbank Robur | 4.3% |
| Board member from Bure: Henrik Blomquist, chairman | Others | 51.1% |

- Net sales increased 9 per cent to SEK 905M (829).
 In local currencies, growth was 3 per cent and 4 per cent excluding divested operations.
- Operating profit before depreciation (EBITDA) amounted to SEK 293M (273), corresponding to a margin of 33 per cent (33).
- The share price decreased 2.7 per cent during the second quarter of 2023.



Share of Bure's net asset value: 7.6%

Xvivo Perfusion is an international medtech company that develops solutions for organ, tissue and cells during transplantation procedures.

| Key figure SEK m | Q2 2023 | Q2 2022 | 6 mth 2023 | 6 mth 2022 | 2022 |
|--------------------------------------|------------|------------|---------------|---------------|-------|
| Net sales | 155 | 94 | 295 | 187 | 415 |
| Operating expenses | -151 | -90 | -280 | -178 | -409 |
| EBIT | 4 | 4 | 15 | 9 | 6 |
| EBIT margin | 2.5% | 4.4% | 5.1% | 4.7% | 1.5% |
| Net financial items | 8 | 6 | 13 | 8 | 16 |
| Profit/loss before tax | 11 | 10 | 28 | 17 | 22 |
| Income tax expense | -5 | -3 | -7 | -4 | -4 |
| Profit/loss for the period | 7 | 8 | 21 | 12 | 18 |
| | | | | | |
| Net loan debt (-)/ receivable (+) | | | 144 | 311 | 237 |
| Total assets | | | 1,788 | 1,585 | 1,733 |
| Equity | | | 1,503 | 1,346 | 1,430 |
| Cash flow from operating activities | | | 3 | -11 | 28 |
| Average no. of employees | | | 142 | 115 | 133 |

| Facts at 30 June 2023 | Largest shareholders | |
|--|-----------------------|-------|
| NAV: SEK 1,326M | Bure Equity | 14.6% |
| Acquisition date: Lex Asea | Fjärde AP-fonden | 9.0% |
| distribution from Vitrolife | Swedbank Robur Fonder | 8.9% |
| in 2012 | Others | 67.5% |
| Board member from Bure: Gösta Johannesson, chairman | | |

- Net sales amounted to SEK 155M, corresponding to an increase of 64 per cent in SEK and 52 per cent in local currencies. Organic growth accounted for 46 per cent and acquired growth for 6 per cent.
- Operating profit before depreciation (EBITDA) amounted to SEK 17M (14), corresponding to a margin of 11 per cent (15).
- During the period, the US FDA granted XVIVO approval to include its heart preservation technology in an IDE clinical trial. The inclusion of patients was completed in the European heart preservation clinical trial.
- The share price increased 24.4 per cent during the second quarter of 2023.

Unlisted portfolio companies

ALLGON

atle

www.allgon.se

Share of Bure's net asset value: 5.5%

Allgon is a world-leading actor in industrial radio remote controls. The company develops, manufactures, and delivers industrial radio remote control solutions for customers worldwide.

| Key figure SEK m | Q2 2023 | Q2 2022 | 6 mth 2023 | 6 mth 2022 | 2022 |
|--------------------------------------|------------|------------|---------------|---------------|-------|
| Net sales | 177 | 156 | 359 | 312 | 617 |
| Operating expenses | -151 | -138 | -295 | -263 | -521 |
| EBIT | 26 | 18 | 64 | 49 | 96 |
| EBIT margin | 14.8% | 11.3% | 17.7% | 15.6% | 15.5% |
| Net financial items | -3 | -2 | -6 | -3 | -6 |
| Profit/loss before tax | 23 | 16 | 58 | 46 | 89 |
| Income tax expense | -3 | -3 | -7 | -7 | -17 |
| Profit/loss for the period | 20 | 13 | 51 | 39 | 73 |
| Net loan debt (-)/ receivable (+) | | | -172 | -170 | -172 |
| Total assets | | | 873 | 813 | 830 |
| Equity | | | 496 | 424 | 460 |
| Cash flow from operating activities | | | 45 | 31 | 60 |
| Average no. of employees | | | 402 | 369 | 377 |

| Facts at 30 June 2023 | Largest shareholders | | | |
|-------------------------|----------------------|-------|--|--|
| NAV: SEK 971M | Bure Equity | 92.6% | | |
| Acquisition date: 2021 | Management and board | | | |
| Board member from Bure: | of Allgon | 7.4% | | |

The quarter in brief

Oskar Hörnell, board member

- Net sales increased 14 per cent to SEK 177M (156).
- Operating profit was SEK 26M (18), corresponding to a margin of 14.8 per cent (11.3).
- Allgon paid share dividends of SEK 20M of which Bure Equity received SEK 18M.
- The holding in Allgon was revalued by SEK 218M.
- Net debt was SEK 172M (170).

www.atle.se

Share of Bure's net asset value: 1.8%

Atle Investment Management invests in financial services and assets. The company owns 30.4% of Alcur Fonder, 100% of Atle Investment Services, 20.1% of Fondbolaget Fondita, 66.7% of HealthInvest Partners, 100% of Humle Fonder, 35.2% of Teknik Innovation Norden Fonder (TIN Fonder) and holdings in equity funds.

| Key figure SEK m | Q2 2023 | Q2 2022 | 6 mth 2023 | 6 mth 2022 | 2022 |
|--------------------------------------|------------|------------|---------------|---------------|------|
| Net sales | 0 | 0 | 0 | 0 | 0 |
| Dividends | 0 | 0 | 62 | 116 | 120 |
| Fair value of financial assets | 1 | 18 | 2 | 16 | 11 |
| Management costs | -3 | -3 | -5 | -4 | -8 |
| EBIT | -2 | 15 | 59 | 128 | 123 |
| Net financial items | -3 | -1 | -4 | -1 | -3 |
| Profit/loss before tax | -5 | 15 | 55 | 127 | 120 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 |
| Profit/loss for the period | -5 | 15 | 55 | 127 | 120 |
| Net loan debt (-)/ receivable (+) | | | -139 | -64 | -73 |
| Total assets | | | 354 | 281 | 284 |
| Equity | | | 201 | 198 | 191 |
| Cash flow from operating activities | | | 49 | 114 | 109 |
| Average no. of employees | | | 1 | 1 | 1 |

1) Of which, SEK 149M is liable to the Parent Company as at 30 June 2023.

| Facts at 30 June 2023 | Largest shareholders | |
|---|----------------------|-------|
| NAV: SEK 320M | Bure Equity | 93.0% |
| Acquisition date: Established 2014 | Gustav Ohlsson | 7.0% |
| Board member from Bure: Henrik Blomquist, chairman | | |

The quarter in brief

Oskar Hörnell, board member

• The value of capital under management in Alcur Fonder, Atle Investment Services, Fondita, HealthInvest Partners, Humle Fonder and TIN Fonder increased to SEK 35 billion compared to SEK 33 billion at the beginning of the year.





Share of Bure's net asset value: 8.3%

Bure Growth is a wholly owned company that invests in development companies. The company owns 46.5% in BioLamina, 30.4% in My Driving Academy Sweden, 28.1% in ScandiNova Systems and 17.6% in Yubico.

| Key figure SEK m | Q2 2023 | Q2 2022 | 6 mth 2023 | 6 mth 2022 | 2022 |
|--|------------|------------|---------------|---------------|-------|
| Net sales | 0 | 0 | 0 | 0 | 0 |
| Fair value of financial assets | 0 | 40 | 59 | 46 | 46 |
| Administrative expense | 0 | 0 | 0 | 0 | 0 |
| EBIT | 0 | 40 | 59 | 46 | 46 |
| Net financial items | 0 | 0 | 0 | 0 | 0 |
| Profit/loss before tax | 0 | 40 | 59 | 46 | 46 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 |
| Profit/loss for the period | 0 | 40 | 59 | 46 | 46 |
| Net loan debt (-)/ receivable (+) ¹⁾ | | | -486 | -449 | -449 |
| Total assets | | | 1 460 | 1 362 | 1 362 |
| Equity | | | 953 | 894 | 894 |
| Cash flow from operating activities | | | 0 | 0 | 0 |
| Average no. of employees | | | 0 | 0 | 0 |

1) Of which, SEK 486M is liable to the Bure Equity as at 30 June 2023.

| Facts at 30 June 2023 | Largest shareholders | |
|-----------------------|----------------------|--------|
| NAV: SEK 1,460M | Bure Equity | 100.0% |

Acquisition date: Established 2015 Board member from Bure: Henrik Blomquist, chairman Sophie Hagströmer, board member Max Jonson, board member

The quarter in brief

• Bure Growth acquired shares in BioLamina for SEK 62M after the end of the period. The shareholding in BioLamina was revalued by SEK 353M.



Share of Bure's net asset value: 0.4%

Mercuri International is a leading sales and management training consultancy and is present worldwide.

| Key figure SEK m | Q2 2023 | Q2 2022 | 6 mth 2023 | 6 mth 2022 | 2022 |
|--|------------|------------|---------------|---------------|------|
| Net sales | 91 | 88 | 171 | 161 | 325 |
| Operating expenses | -84 | -83 | -165 | -160 | -323 |
| EBIT | 7 | 5 | 6 | 1 | 2 |
| EBIT margin | 7.8% | 5.5% | 3.4% | 0.7% | 0.5% |
| Net financial items | 0 | 2 | -1 | 2 | -1 |
| Profit/loss before tax | 7 | 6 | 5 | 3 | 1 |
| Income tax expense | 0 | -1 | 0 | -2 | -6 |
| Profit/loss for the period | 7 | 5 | 5 | 1 | -5 |
| Net loan debt (-)/ receivable (+)1) | | | -102 | -103 | -92 |
| Total assets | | | 347 | 332 | 346 |
| Equity | | | 133 | 109 | 118 |
| Cash flow from operating activities | | | -7 | -21 | -8 |
| Average no. of employees | | | 189 | 200 | 194 |

1) Of which, SEK 33M is liable to the Bure Equity as at 31 March 2023.

| Facts at 30 June 2023 | Largest shareholders | |
|---|----------------------|-------|
| NAV: SEK 68M ¹⁾ | Bure Equity | 90.4% |
| Acquisition date: 1998 | Others | 9.6% |
| Board member from Bure: Henrik Blomquist, chairman | | |

1) Fair value of equity and interest-bearing receivables.

- Sales increased 3 per cent to SEK 91M (88).
- EBIT was SEK 7M (5) and EBIT margin was 7.8 per cent (5.5).

Interim report January – June 2023

Bure is an investment entity, which means that the holdings varies in line with its acquisitions and divestitures. Since this makes the Group's consolidated statements difficult to analyse, the development and financial position of the companies should also be analysed on an individual basis. More detailed information on portfolio companies are presented on pages 6–11.

Consolidation principles from 1 January 2021

Bure Equity is an investment entity in accordance with IFRS 10 – Investment entity.

An investment company does not consolidate subsidiaries in accordance with IFRS 10 Consolidated Financial Statements and does not apply IFRS 3 Business Combinations, with the exception of subsidiaries that are active in investment activities. An investment entity values portfolio companies at fair value in accordance with IFRS 9 Financial Instruments.

Since 1 January 2021, the Bure Group consists of the parent company Bure Equity AB, Atle Investment Management AB, and Bure Growth AB. For more information, please see Note 1 – Accounting principles.

GROUP

Results for the second quarter of 2023

Group earnings from investment activities amounted to SEK 753M (-2,555).

Dividends amounted to SEK 129M (96).

Fair value changes from financial assets amounted to SEK 621M (-2,653).

Operating profit for the period was SEK 727M (-2,590). Net financial items amounted to SEK 2M (4).

Profit after financial items was SEK 729M (-2,586).

Profit after tax was SEK 729M (-2,586).

Other comprehensive income included translation differences of SEK 0M (0).

Results for January - June 2023

Group earnings from investment activities amounted to SEK 3,187M (-9,156).

Dividends amounted to SEK 191M (212).

Fair value changes from financial assets amounted to SEK 2,992M (-9,372).

Operating profit for the period was SEK 3,145M (-9,207). Net financial items amounted to SEK 5M (6). Profit after financial items was SEK 3,150M (-9,202).

Profit after tax was SEK 3,150M (-9,202). Other comprehensive income included translation differences of SEK 0M (0).

Financial position

Group equity at the end of the period amounted to SEK 17,529M (14,579) and the equity to assets ratio was 100 per cent (100). At the end of the period, the group had reported net receivables of SEK 225M (478), which consisted of interest-bearing assets of SEK 227M (482) and interest-bearing liabilities of SEK 2M (4). Group equity per share amounted to SEK 236.1 compared to SEK 195.9 per share on December 31, 2022.

PARENT COMPANY Results for the second quarter of 2023

Earnings from investment activities was SEK 794M (-2,507).

Dividends amounted to SEK 171M (202).

Fair value changes from financial assets amounted to SEK 620M (-2,712).

Administrative costs amounted to SEK 22M (32). Net financial items amounted to SEK 5M (4). Profit after tax was SEK 776M (-2,536).

Results for January - June 2023

Earnings from investment activities was SEK 3,107M (-9,227).

Dividends amounted to SEK 171M (202).

Fair value changes from financial assets amounted to SEK 2,931M (-9,433).

Administrative costs amounted to SEK 37M (48). Net financial items amounted to SEK 9M (6). Profit after tax was SEK 3,078M (-9,269).

Financial position

Equity in the Parent Company at the end of the period amounted to SEK 16,397 M (13,509) and the equity to assets ratio was 100 per cent (100). At the end of the period, the Parent Company had a reported net receivables of SEK 356M (542), which consisted of interest-bearing assets of 358M (545) and interest-bearing liabilities of SEK 2M (4). Receivables from Atle Investment Management and Bure Growth amounted to SEK 635M (530).

Group acquisitions and disposals

Bure subscribed to shares for SEK 58M in Cavotec's rights issue.

Bure subscribed to shares for SEK 50M in Ovzon's rights issue

Atle paid an additional purchase price for Atle Investment Services and HealthInvest Partners of SEK 60M.

Atle made a conditional shareholder contribution to Atle Investment Services of SEK 8M.

Bure Growth subscribed to shares for SEK 36M in ScandiNova Systems' rights issue. The holding was revalued by SEK 61M due to the transaction.

Bure issued 150,000 purchase options and divested 175,000 shares in Cavotec to members of the Cavotec management team for a total of SEK 3M.

Group loss carryforward

Group loss carryforward at the end of 30 June 2023 amounted to SEK 789M, of which SEK 762M pertained to the Parent Company. Losses attributable to Sweden amounted to SEK 789M and are perpetual. The deferred tax asset based on loss carryforwards in the Group has been valued at SEK 0M (0).

Currency exposure

The majority of consolidated revenue is denominated in SEK and EUR. Underlying costs are generally incurred in the same currency as revenues, thereby limiting transaction exposure.

Related party transactions

ACQ Bure AB (publ.) is a Swedish acquisition company listed on the Nasdaq Stockholm. Bure's holding in ACQ Bure amounts to 20 per cent. Since 21 December 2020, Henrik Blomquist, (CEO of Bure Equity), has served as CEO of ACQ Bure on a consulting basis, Max Jonson, (CFO of Bure Equity), has served as CFO on a consulting basis and Oskar Hörnell (Investment Manager of Bure Equity) has served as a consultant of ACQ Bure. Bure Equity also assists ACQ Bure with investment advisory services. Contracts are entered into on market terms. Bure Equity has invoiced ACQ Bure since the beginning of the second quarter of 2021. No other transactions with related parties have taken place during the period.

Ownership structure

Bure's largest shareholders on 30 June 2023 were Patrik Tigerschiöld including related parties with 10.4 per cent, AMF Tjänstepension & Fonder 9.9 per cent, the Björkman family including foundations with 8.2 per cent, Fjärde AP-fonden 7.8 per cent and SEB Investment Management 5.9 per cent. According to Euroclear, the number of shareholders on 30 June 2023 was 56,278.

Events after the balance sheet date

Bure Growth acquired shares in BioLamina for SEK 62M. The shareholding in BioLamina was revalued by SEK 353M.

Significant risks and uncertainties

In view of the rapid on the financial markets, special emphasis is placed on monitoring the effects of Bure's investments and their valuations. Bure has a number of basic principles regarding the management of risk. Bure's financial policy states that the Parent Company shall be essentially debt-free. Furthermore, each portfolio company shall be financially independent from the Parent Company, which means that the Parent Company is not financially liable for portfolio companies' obligations, and that portfolio companies are responsible for their own financing.

Financing of respective portfolio companies shall be appropriate to each company's specific circumstances, such that overall risk is managed through a balance between operational and financial risk.

Bure's 2022 annual report provides a detailed description of the Group's risk exposure and risk management in the administration report and in Note 15. Bure's assessment is that no significant risks have arisen other than those described in the annual report and in this interim report. This interim report has not been subject to review by the auditors.

Stockholm 18 August 2023 Bure Equity AB (publ)

| Patrik Tigerschiöld (Chairman) | Carl Björkman | Carsten Browall |
|-----------------------------------|------------------|---------------------------|
| Charlotta Falvin | Sarah McPhee | Birgitta Stymne Göransson |
| | Henrik Blomquist | |

(CEO)

Statement of comprehensive income

| SEK M | Q2 2023 | Q2 2022 | 6 mth 2023 | 6 mth 2022 | Full year 2022 |
|---|------------|------------|---------------|---------------|-------------------|
| Operating income | | | | | |
| Net sales | 0 | 0 | 0 | 0 | 0 |
| Dividends | 129 | 96 | 191 | 212 | 217 |
| Fair value financial assets | 621 | -2,653 | 2,992 | -9,372 | -9,390 |
| Other operating income | 3 | 2 | 4 | 4 | 7 |
| Total operating income | 753 | -2,555 | 3,187 | -9,156 | -9,166 |
| Operating expenses | | | | | |
| Other external expenses | -8 | -9 | -15 | -15 | -26 |
| Personnel costs | -16 | -25 | -25 | -34 | -49 |
| Amortization and write-downs of intangible and | | | | | |
| tangible fixed assets | -1 | -1 | -2 | 2 | -4 |
| Total operating expenses | -25 | -35 | -42 | -52 | -80 |
| Operating profit/loss | 727 | -2,590 | 3,145 | -9,207 | -9,246 |
| Interest income and similar profit/loss items | 2 | 4 | 5 | 6 | 12 |
| Interest expenses and similar profit/loss items | 0 | 0 | 0 | 0 | 0 |
| Profit/loss after financial items | 729 | -2,586 | 3,150 | -9,202 | -9,235 |
| Tax on income for the period | 0 | 0 | 0 | 0 | 0 |
| Income for the period | 729 | -2,586 | 3,150 | -9,202 | -9,235 |
| Other comprehensive income | | | | | |
| Items that can be subsequently re-entered onto | | | | | |
| the income statement | | | | | |
| Translation differences | 0 | 0 | 0 | 0 | 0 |
| Other comprehensive income for the period, after tax | 0 | 0 | 0 | 0 | 0 |
| Total income for the period | 729 | -2,586 | 3,150 | -9,202 | -9,235 |
| | | | | | |
| Profit/loss attributable to non-controlling interests | 0 | 1 | 4 | 9 | 8 |
| Profit/loss attributable to owners of the Parent Company | 730 | -2,587 | 3,146 | -9,211 | -9,243 |
| Comprehensive income attributable to non-controlling interests | 0 | 1 | 4 | 9 | 8 |
| Comprehensive income attributable to non-controlling interests | 730 | -2,587 | 3,146 | -9,211 | -9,243 |
| | ,,,, | 2,007 | 5,1.0 | 3,211 | 3,2.0 |
| Average number of outstanding shares before dilution, thousands ¹⁾ | 74,147 | 74,147 | 74,147 | 74,147 | 74,147 |
| Average number of outstanding shares post dilution, thousands ¹⁾ | 74,252 | 74,147 | 74,252 | 74,147 | 74,161 |
| | , | ,= :: | , | ,,,,,,,, | , |
| Earnings per share attributable to the parent company's shareholders before dilution, SEK ¹⁾ | 9,84 | -34,89 | 42,43 | -124,22 | -124,66 |
| Earnings per share attributable to the parent company's shareholders post dilution, SEK ¹⁾ | 9,83 | -34,89 | 42,37 | -124,22 | -124,66 |

¹⁾ As of 30 June 2023 and 31 December 31, 2022, the number of possible additional ordinary shares amounts to 105,136. No dilutive effect as of 30 June 2022.

Statement of financial position

| SEK M | 30 June 2023 | 30 June 2022 | 31 December 2022 |
|--|-----------------|-----------------|------------------|
| Assets | | | |
| Intangible and tangible fixed assets | 34 | 30 | 36 |
| Financial assets valued at fair value via the income statement | 17,175 | 13,996 | 14,027 |
| Long-term interest-bearing receivables | 41 | 32 | 41 |
| Long-term non-interest-bearing receivables | 1 | 1 | 1 |
| Financial assets | 17,217 | 14,029 | 14,069 |
| Total fixed assets | 17,251 | 14,058 | 14,105 |
| Short-term interest-bearing receivables | 1 | 2 | 2 |
| Other non-interest-bearing receivables | 11 | 7 | 4 |
| Financial investments | 124 | 106 | 116 |
| Cash and cash equivalents | 185 | 448 | 416 |
| Total current assets | 320 | 563 | 538 |
| Total assets | 17,571 | 14,622 | 14,643 |
| of which, interest-bearing assets | 227 | 482 | 459 |
| Equity and liabilities | | | |
| Equity attributable to owners of the Parent Company | 17,515 | 14,566 | 14,535 |
| Equity attributable to non-controlling interests | 14 | 14 | 13 |
| Total equity | 17,529 | 14,579 | 14,548 |
| Provisions | 21 | 19 | 19 |
| Non-current liabilities | 1 | 2 | 53 |
| Current liabilities | 20 | 21 | 23 |
| Total liabilities | 41 | 42 | 95 |
| Total equity and liabilities | 17,571 | 14,622 | 14,643 |
| of which, interest-bearing liabilities | 2 | 4 | 3 |

Statement of changes in equity

| Attributable to Bure Equity AB's shareholders | | | | | | | |
|---|------------------|---------------------------|----------|---|--------|---------------------------|--------------|
| SEK M | Share capital | Other contributed capital | Reserves | Retained earnings incl. profit for the period | Total | Non-controlling interests | Total equity |
| Opening balance equity at 1 January 2022 | 576 | 1,660 | -60 | 21,768 | 23,943 | 13 | 23,956 |
| Profit/loss for the year | _ | _ | _ | -9,243 | -9,243 | 8 | -9,235 |
| Other comprehensive income | _ | _ | _ | 0 | 0 | _ | 0 |
| Share-related remuneration LTIP 2022 | _ | _ | _ | 1 | 1 | - | 1 |
| Issue of class C shares | 1 | _ | _ | - | 1 | - | 1 |
| Buyback of class C shares | - | _ | _ | -1 | -1 | _ | -1 |
| Cash dividend | - | _ | _ | -167 | -167 | _ | -167 |
| Dividends paid to minority shareholders | _ | _ | _ | _ | - | -8 | -8 |
| Closing balance equity at 31 December 2022 | 577 | 1,660 | -60 | 12,359 | 14,535 | 13 | 14,548 |
| Opening balance equity at 1 January 2023 | 577 | 1,660 | -60 | 12,359 | 14,535 | 13 | 14,548 |
| Profit/loss for the period | - | _ | _ | 3,146 | 3,146 | 4 | 3,150 |
| Other comprehensive income | - | _ | _ | 0 | 0 | _ | 0 |
| Share-related remuneration LTIP 2022 | - | _ | _ | 1 | 1 | _ | 1 |
| Share-related remuneration LTIP 2023 | - | _ | _ | 0 | 0 | - | 0 |
| Cash dividend | _ | _ | _ | -167 | -167 | - | -167 |
| Dividends paid to minority shareholders | _ | _ | _ | _ | - | -3 | -3 |
| Closing balance equity at 30 June 2023 | 577 | 1,660 | -60 | 15,340 | 17,515 | 14 | 17,529 |

Statement of cash flows

| | Q2 | Q2 | 6 mth | 6 mth | Full year |
|---|------|------|-------|-------|-----------|
| SEK M | 2023 | 2022 | 2023 | 2022 | 2022 |
| Cash flow from operating activities before changes in working capital | 114 | 67 | 161 | 187 | 176 |
| Cash flow from changes in working capital | -6 | -4 | -10 | -5 | 0 |
| Cash flow from operating activities | 108 | 63 | 150 | 182 | 176 |
| | | | | | |
| Cash flow from investing activities | 0 | -26 | -159 | 116 | 39 |
| Cash flow from financing activities | -171 | -175 | -222 | -175 | -125 |
| Cash flow for the period | -63 | -139 | -231 | 122 | 90 |
| Cash and cash equivalents at beginning of period | 248 | 587 | 416 | 326 | 326 |
| Cash flow for the period | -63 | -139 | -231 | 122 | 90 |
| Translation differences | 0 | 0 | 0 | 0 | 0 |
| Cash and cash equivalents at end of period | 185 | 448 | 185 | 448 | 416 |

Income statement

| | Q2 | Q2 | 6 mth | 6 mth | Full year |
|---|----------|--------|--------|---------|-----------|
| SEK M | 2023 | 2022 | 2023 | 2022 | 2022 |
| Investment activities | | | | | |
| Dividends | 171 | 202 | 171 | 202 | 202 |
| Fair value financial assets | 620 | -2 712 | 2 931 | -9 433 | -9 446 |
| Other income | 3 | 2 | 4 | 4 | 7 |
| Total income | 794 | -2 507 | 3 107 | -9 227 | -9 237 |
| Personnel costs | -15 | -24 | -23 | -32 | -46 |
| Other external expenses | -7 | -8 | -13 | -15 | -24 |
| Depreciation of property, plant and equipment | -1 | -1 | -1 | -1 | -2 |
| Total management costs | -22 | -32 | -37 | -48 | -72 |
| Operating profit/loss | 772 | -2 540 | 3 070 | -9 275 | -9 309 |
| Financial income and expenses | | | | | |
| Interest income and similar profit/loss items | 5 | 4 | 9 | 7 | 15 |
| Interest expenses and similar profit/loss items | 0 | 0 | 0 | 0 | 0 |
| Total financial income and expenses | 5 | 4 | 9 | 6 | 15 |
| Total Illiancial Illcome and expenses | <u> </u> | 4 | 9 | 0 | 15 |
| Financial income and expenses | 776 | -2 536 | 3 078 | -9 269 | -9 294 |
| Tax on income for the period | 0 | 0 | 0 | 0 | 0 |
| Profit/loss for the period 1) | 776 | -2 536 | 3 078 | -9 269 | -9 294 |
| Average number of outstanding shares before dilution, thousands ¹⁾ | 74 147 | 74 147 | 74 147 | 74 147 | 74 147 |
| Average number of outstanding shares post dilution, thousands ¹⁾ | 74 252 | 74 147 | 74 147 | 74 147 | 74 147 |
| Average number of outstanding shares post unution, thousands | 74 202 | 74 147 | 74 252 | 74 147 | 74 101 |
| Earnings per share attributable to the parent company's shareholders before dilution, SEK ¹⁾ | 10,47 | -34,20 | 41,52 | -125,01 | -125,35 |
| Earnings per share attributable to the parent company's shareholders post dilution, SEK ¹⁾ | 10,45 | -34,20 | 41,46 | -125,01 | -125,35 |
| Average number of employees | 8 | 8 | 8 | 8 | 9 |

¹⁾ Corresponds to comprehensive income.
2) As of 30 June 2023 and of 31 December 2022, the number of possible additional ordinary shares amounts to 105,136. No dilutive effect as of 30 June 2022.

Statement of financial position

| SEK M | 30 June 2023 | 30 June 2022 | 31 December 2022 |
|--|-----------------|-----------------|---------------------|
| Assets | | | |
| Property, plant and equipment | 7 | 8 | 8 |
| Financial assets valued at fair value via the income statement | 15,426 | 12,400 | 12,394 |
| Shares in group companies | 21 | 21 | 21 |
| Long-term interest-bearing receivables | 33 | 32 | 33 |
| Long-term non-interest-bearing receivables | 1 | 1 | 1 |
| Financial assets | 15,480 | 12,453 | 12,448 |
| Total fixed assets | 15,487 | 12,462 | 12,456 |
| Short-term interest-bearing receivables | 150 | 83 | 83 |
| Other non-interest-bearing receivables | 500 | 458 | 456 |
| Short-term investments | 104 | 98 | 98 |
| Cash and cash equivalents | 175 | 431 | 408 |
| Total current assets | 929 | 1,070 | 1,045 |
| Total assets | 16,416 | 13,531 | 13,501 |
| of which, interest-bearing assets | 358 | 545 | 523 |
| Equity and liabilities | | | |
| Total equity | 16,397 | 13,509 | 13,484 |
| Provisions | 0 | 0 | 0 |
| Non-current liabilities | 1 | 2 | 2 |
| Current liabilities | 19 | 20 | 15 |
| Total liabilities | 19 | 22 | 17 |
| Total equity and liabilities | 16,416 | 13,531 | 13,501 |
| of which, interest-bearing liabilities | 2 | 4 | 3 |

Statement of changes in equity

| | Q2 | Q2 | 6 mth | 6 mth | Full year |
|--------------------------------------|--------|--------|--------|--------|-----------|
| SEK M | 2023 | 2022 | 2023 | 2022 | 2022 |
| Equity at beginning of period | 15,787 | 16,211 | 13,484 | 22,944 | 22,944 |
| Share-related remuneration LTIP 2022 | 0 | _ | 1 | _ | 1 |
| Share-related remuneration LTIP 2023 | 0 | _ | 0 | _ | _ |
| Issue of class C shares | _ | _ | _ | _ | 1 |
| Buyback of class C shares | _ | _ | _ | _ | -1 |
| Cash dividend | -167 | -167 | -167 | -167 | -167 |
| Profit/loss for the period | 776 | -2,536 | 3,078 | -9,269 | -9,294 |
| Closing balance, equity | 16,397 | 13,509 | 16,397 | 13,509 | 13,484 |

Statement of cash flows

| | Q2 | Q2 | 6 mth | 6 mth | Full year |
|---|------|------|-------|-------|-----------|
| SEK M | 2023 | 2022 | 2023 | 2022 | 2022 |
| Cash flow from operating activities before changes in working capital | 161 | 172 | 150 | 179 | 169 |
| Cash flow from changes in working capital | -8 | -5 | -6 | -6 | -10 |
| Cash flow from operating activities | 152 | 167 | 144 | 173 | 159 |
| Cash flow from investing activities | 0 | -34 | -209 | 130 | 121 |
| Cash flow from financing activities | -167 | -167 | -168 | -167 | -168 |
| Cash flow for the period | -15 | -35 | -233 | 135 | 112 |
| Cash and cash equivalents at beginning of period | 190 | 465 | 408 | 296 | 296 |
| Cash flow for the period | -15 | -35 | -233 | 135 | 112 |
| Cash and cash equivalents at end of period | 175 | 431 | 175 | 431 | 408 |

Multi-year overview

| Data per share 1) | 30 June 2023 | 2022 | 2021 | 2020 | 2019 |
|---|-----------------|--------|--------|--------|--------|
| Net asset value, SEK 2) | 236.4 | 196.3 | 323.2 | 239.6 | 196.6 |
| Share price, SEK | 250.6 | 246.4 | 438.2 | 293.6 | 212.0 |
| Share price as a percentage of net asset value | 106% | 125% | 136% | 123% | 108% |
| Parent Company basic equity per share, SEK | 220.8 | 181.6 | 309.4 | 226.8 | 183.6 |
| Parent Company equity per share excl. buybacks, SEK | 221.1 | 181.9 | 309.4 | 226.8 | 183.6 |
| Group basic equity per share, SEK | 236.1 | 195.9 | 323.1 | 238.7 | 196.8 |
| Group equity per share excl. buybacks, SEK | 236.4 | 196.2 | 323.1 | 238.7 | 196.8 |
| Parent Company basic earnings per share, SEK 33 | 41.5 | -125.3 | 84.1 | 45.2 | 55.8 |
| Group basic earnings per share, SEK 3) | 42.4 | -124.7 | 85.8 | 45.1 | 61.3 |
| Number of shares, thousands | 74,252 | 74,252 | 74,147 | 74,147 | 68,972 |
| Number of shares excluding share buybacks, thousands | 74,147 | 74,147 | 74,147 | 74,147 | 68,972 |
| Average basic number of shares, thousands | 74,252 | 74,161 | 74,147 | 71,757 | 68,972 |
| Key figures | | | | | |
| Dividend, SEK per share | 2.25 | 2.25 | 2.0 | 1.0 | 2.0 |
| of which, extraordinary dividend, SEK per share | - | _ | _ | _ | _ |
| Direct return | 0.9% | 0.9% | 0.5% | 0.3% | 0.9% |
| Total return | 2.6% | -43.1% | 50.1% | 39.2% | 97.9% |
| Market capitalisation, SEK M | 18,581 | 18,270 | 32,491 | 21,770 | 14,622 |
| Net asset value, SEK M | 17,531 | 14,559 | 23,964 | 17,763 | 13,563 |
| Return on equity | 20.6% | -48.0% | 31.3% | 22.0% | 35.6% |
| Management expenses/Net asset value | 0.42% | 0.49% | 0.30% | 0.29% | 0.33% |
| Parent Company results and financial position | | | | | |
| Profit/loss after tax, SEK M | 3,078 | -9,294 | 6,237 | 3,242 | 3,850 |
| Total assets, SEK M | 16,416 | 13,501 | 22,972 | 16,845 | 12,688 |
| Equity, SEK M | 16,397 | 13,484 | 22,944 | 16,819 | 12,662 |
| Equity/assets ratio | 100% | 100% | 100% | 100% | 100% |
| Cash and cash equivalents and short-term investments, SEK M | 279 | 506 | 417 | 1,460 | 800 |
| Consolidated profit and financial position | | | | | |
| Net sales, SEK M | 0 | 0 | 0 | 267 | 382 |
| Profit/loss after tax, SEK M | 3,150 | -9,235 | 6,362 | 3,236 | 4,229 |
| Total assets, SEK M | 17,571 | 14,643 | 24,004 | 17,935 | 13,786 |
| Equity, SEK M | 17,529 | 14,548 | 23,956 | 17,702 | 13,573 |
| Equity/assets ratio | 100% | 99% | 100% | 99% | 98% |
| Net loan debt (-)/receivable (+), SEK M | 225 | 456 | 469 | 1,166 | 648 |
| Average number of employees | 9 | 10 | 9 | 229 | 226 |

¹⁾ All historical data per share have been adjusted for shares in issue with a time-weighting factor as prescribed by IAS 33.

²⁾ Net asset value consists of the market value of Bure's listed and unlisted holdings, short term investments, other net assets and cash and cash equivalents.

3) As of 30 June 2023 and of 31 December 2022, the number of possible additional ordinary shares amounts to 105,136. There was no dilution effect during the periods.

Notes

Note 1 - Accounting policies

Bure applies International Financial Reporting Standards (IFRS) as endorsed for application in the EU. This interim report has been prepared in compliance with IAS 34, Interim Financial Reporting, the Swedish Annual Accounts Act and the Swedish Financial Reporting Board's recommendation RFR 2, Accounting for Legal Entities.

Group consolidation principles

Bure Equity is an investment entity in accordance with IFRS 10 – Investment entity.

An investment entity does not consolidate subsidiaries in accordance with IFRS 10 Consolidated Financial Statements and does not apply IFRS 3 Operating Acquisitions with the exception of subsidiaries that are active in investing activities. An investment entity values portfolio companies at fair value in accordance with IFRS 9 Financial Instruments.

Since 1 January 2021, the Bure Group consists of the parent company Bure Equity AB, Atle Investment Management AB and Bure Growth AB.

Parent company accounting principles

The parent company's investments in companies and other financial assets are reported at fair value as profit and loss in the same way as for the group.

For further information on accounting and valuation principles, please see Note 1 in the 2022 annual report.

New accounting principles applied from 1 January 2023: revised or amended IFRS standards are not considered to have any significant impact on earnings or balance statements. Bure continuously updates its analysis of upcoming changes.

Note 2 - Segment reporting

All activities in the entity are considered to constitute a single segment.

Note 3 - Effects of changed estimates and assessments

Important estimates and assessments are presented in Note 1 in the 2022 annual report. No changes to these estimates and assessments have been that could have a significant impact on the current interim report.

Note 4 - Financial instruments

Fair value and book value of financial assets and liabilities

Fair value has been calculated for all financial assets and liabilities in accordance with IFRS 13. Fair value is estimated to be equal to the book value of accounts receivable and other receivables, other current receivables, cash and other cash and cash equivalents, accounts payable, and other liabilities and borrowing. Book value less write-downs is an estimated fair value for accounts receivable and accounts payable. For long-term non-interest-bearing liabilities, fair value has been calculated by discounting future cash flows with current market interest rates regarding the term of the debt.

The investment entity's financial assets and liabilities are classified in accordance with IFRS 13 in the following three categories

- Level 1: Listed prices in an active market for identical assets or liabilities.
- Level 2: Other observable data for the asset or liability other than listed prices included in Level 1, either directly or indirectly.
- Level 3: Data for the asset or liability that are not in their entirety based on observable market data.

Bure reports listed holdings at fair value with changes in value in the income statement (level 1). Bure's listed holdings consist of

ACQ Bure AB, Cavotec SA, Mentice AB, Mycronic AB, Ovzon AB, Vitrolife AB, and Xvivo Perfusion AB.

Bure reports unlisted holdings at fair value (level 3). Bure's unlisted holdings consist of Allgon AB, Alcur Fonder AB, AMIP AB, Atle Investment Services AB, BioLamina AB, Fondbolaget Fondita Ab, HealthInvest Partners AB, Mercuri International Group AB, My Driving Academy Sweden AB, ScandiNova Systems AB, Teknik Innovation Norden Fonder AB and Yubico AB.

Bure has chosen to market value all financial assets based on International Private Equity and Venture Capital Valuation Guidelines (IPEV). The guidelines describe a number of methods for determining the fair value of each holding. Considerable emphasis is placed on recently completed market transactions in the company, e.g., share issues or the acquisition of existing shares. Transactions in comparable companies can also be used. Other valuation methods include discounting of forecast cash flows with relevant discount rates and applying valuation multiples such as EV/Sales, EV/EBITDA, EV/EBITA, EV/EBIT, PER and P/AuM which are adjusted to take into account differences in market, business, and risk. In general, a liquidity discount is also applied for unlisted assets. Valuation takes place on an ongoing basis and is published in conjunction with quarterly reports.

Real value hierarchy, Group

| | | 30 Jun | e 2023 | | | 30 Jun | e 2022 | | 3 | 1 Decem | ber 2022 | |
|--|---------|---------|---------|--------|---------|---------|---------------|--------|---------|---------|----------|--------|
| SEK M | Level 1 | Level 2 | Level 3 | Total | Level 1 | Level 2 | Level 3 | Total | Level 1 | Level 2 | Level 3 | Total |
| Financial assets Financial assets at fair value from the | 17,108 | 67 | | 17,175 | 13,949 | 47 | | 13,996 | 11,550 | | 0.400 | 14,027 |
| income statement Other long-term receivables | 17,108 | - | 41 | 42 | 13,949 | 47 | 32 | 33 | 11,550 | 55 | 41 | 14,027 |
| Financial investments | 124 | _ | | 124 | 106 | _ | _ | 106 | 116 | _ | | 110 |
| Total financial assets | 17,232 | 67 | 41 | 17,341 | 14,056 | 47 | 32 | 14,135 | 11,667 | 55 | 2,463 | 14,185 |
| Financial liabilities Leasing liabilities | - | _ | 2 | 2 | _ | _ | 4 | 4 | _ | - | 3 | 3 |
| Other long-term liabilities | 1 | _ | _ | 1 | 1 | _ | _ | 1 | 1 | _ | 51 | 52 |
| Accrued expenses and prepaid income | _ | - | 12 | 12 | _ | - | 17 | 17 | _ | - | 11 | 11 |
| Total financial liabilities | 1 | - | 14 | 15 | 1 | - | 21 | 22 | 1 | - | 65 | 66 |

Note 4 - Financial instruments (cont.)

Valuation of unlisted assets at 30 June 2023

| SEK M | Holding | Group book value | Valuation model |
|---|---------------|------------------|------------------------------|
| Holdings in Bure Equity AB | | | |
| Allgon AB and AMIP AB | 91.1% / 17.1% | 971 | EV/EBIT, PER |
| Mercuri International Group AB | 90.4% | 68 | EV/EBIT, DCF |
| Holdings in Atle Investment Management AB | | 345 | |
| Alcur Fonder AB | 30.4% | | P/AuM |
| Atle Investment Services AB | 100.0% | | Accrued acquisition value |
| Fondbolaget Fondita Ab | 20.1% | | P/AuM, EV/EBIT |
| HealthInvest Partners AB | 66.7% | | Accrued acquisition value |
| Teknik Innovation Norden Fonder AB | 35.2% | | P/AuM |
| Holdings in Bure Growth AB | | 1,460 | |
| BioLamina AB | 46.5% | | Latest transaction |
| My Driving Academy Sweden AB | 30.4% | | Latest transaction, DCF |
| ScandiNova Systems AB | 28.2% | | Latest transaction |
| Yubico AB ¹⁾ | 15.3% | | Latest transaction, EV/Sales |

¹⁾ Holding amounts to 17.6 per cent before dilution.

Valuation of unlisted assets at 30 June 2022

| SEK M | Holding | Group book value | Valuation model |
|---|-------------|------------------|---------------------------|
| Holdings in Bure Equity AB | | | |
| Allgon AB and AMIP AB | 91.1%/14.5% | 746 | Accrued acquisition value |
| Mercuri International Group AB | 90.4% | 130 | EV/EBIT, DCF |
| Holdings in Atle Investment Management AB | | 246 | |
| Alcur Fonder AB | 30.4% | | P/AuM |
| Atle Investment Services AB | 100.0% | | Accrued acquisition value |
| Fondbolaget Fondita Ab | 20.1% | | P/AuM, EV/EBIT |
| HealthInvest Partners AB | 51.0% | | Accrued acquisition value |
| Teknik Innovation Norden Fonder AB | 35.2% | | P/AuM |
| Holdings in Bure Growth AB | | 1,362 | |
| BioLamina AB | 46.5% | | Latest transaction |
| My Driving Academy Sweden AB | 30.4% | | Latest transaction, DCF |
| ScandiNova Systems AB | 28.0% | | Latest transaction |
| Yubico AB | 17.6% | | Latest transaction |

Valuation of unlisted assets at 31 December 2022

| SEK M | Holding | Group book value | Valuation model |
|---|---------------|------------------|------------------------------|
| Holdings in Bure Equity AB | | | |
| Allgon AB and AMIP AB | 91.1% / 14.5% | 753 | EV/EBIT, PER |
| Mercuri International Group AB | 90.4% | 68 | EV/EBIT, DCF |
| Holdings in Atle Investment Management AB | | 272 | |
| Alcur Fonder AB | 30.4% | | P/AuM |
| Atle Investment Services AB | 100.0% | | Accrued acquisition value |
| Fondbolaget Fondita Ab | 20.1% | | P/AuM, EV/EBIT |
| HealthInvest Partners AB | 45.8% | | Accrued acquisition value |
| Teknik Innovation Norden Fonder AB | 35.2% | | P/AuM |
| Holdings in Bure Growth AB | | 1,362 | |
| BioLamina AB | 46.5% | | Latest transaction |
| My Driving Academy Sweden AB | 30.4% | | Latest transaction, DCF |
| ScandiNova Systems AB | 27.9% | | Latest transaction, EV/EBIT |
| Yubico AB | 17.6% | | Latest transaction, EV/Sales |

Note 5 - Classification of financial instruments

| Group 30 June 2023 SEK M | Financial assets and liabilities valued at fair value from income statements | Financial assets and liabilities valued at accrued acquisition cost | Total carrying amount |
|--|--|---|--------------------------|
| Financial assets | | | |
| Financial assets valued at fair value from the income statements | 17,175 | _ | 17,175 |
| Other long-term receivables | _ | 41 | 41 |
| Other short-term receivables | _ | 4 | 4 |
| Short-term investments | 124 | _ | 124 |
| Cash and bank balances | _ | 185 | 185 |
| Total financial assets | 17,299 | 230 | 17,529 |
| Financial liabilities | | | |
| Leasing liabilities | _ | 2 | 2 |
| Other long-term liabilities | - | 1 | 1 |
| Other non-interest-bearing liabilities | _ | 17 | 17 |
| Total financial liabilities | - | 20 | 20 |
| Group 30 June 2022 SEK M | Financial assets and liabilities valued at fair value from income statements | Financial assets and liabilities valued at accrued acquisition cost | Total carrying amount |
| Financial assets | | | |
| Financial assets valued at fair value from the income statements | 13,996 | _ | 13,996 |
| Other long-term receivables | _ | 32 | 32 |
| Other short-term receivables | - | 9 | 9 |
| Short-term investments | 106 | - | 106 |
| Cash and bank balances | _ | 448 | 448 |
| Total financial assets | 14,102 | 489 | 14,592 |
| Financial liabilities | | | |
| Leasing liabilities | | 4 | 4 |
| Other long-term liabilities | | 1 | 1 |
| Other non-interest-bearing liabilities | | 21 | 21 |
| Total financial liabilities | | 25 | 25 |
| Group 31 December 2023 SEK M | Financial assets and liabilities valued at fair value from income statements | Financial assets and liabilities valued at accrued acquisition cost | Total carrying amount |
| Financial assets | | | |
| Financial assets valued at fair value from the income statements | 14,027 | - | 14,027 |
| Other long-term receivables | _ | 42 | 42 |
| Other short-term receivables | _ | 4 | 4 |
| Short-term investments | 116 | - | 116 |
| Cash and bank balances | _ | 416 | 416 |
| Total financial assets | 14,144 | 461 | 14,605 |
| Financial liabilities | | | |
| Leasing liabilities | _ | 3 | 3 |
| Other long-term liabilities | _ | 52 | 52 |
| Other non-interest-bearing liabilities | | 21 | 21 |
| Total financial liabilities | _ | 76 | 76 |

Note 6 - Financial position

Net loan receivable: Cash and cash equivalents, interest-bearing investments and interest-bearing current and non-current receivables minus interest-bearing current and non-current liabilities.

| Group, SEK M | 30 June 2023 | 30 June 2022 | 31 December 2022 |
|--|--------------|--------------|------------------|
| Cash and cash equivalents | 185 | 448 | 416 |
| Current interest-bearing receivables | 1 | 2 | 2 |
| Non-current interest-bearing receivables | 41 | 32 | 41 |
| Interest-bearing assets | 227 | 482 | 459 |
| Current interest-bearing leasing liabilities | 2 | 2 | 2 |
| Non-current interest-bearing leasing liabilities | 0 | 2 | 1 |
| Interest-bearing liabilities | 2 | 4 | 3 |
| Net receivable at end of the year | 225 | 478 | 456 |
| Parent Company, SEK M | 30 June 2023 | 30 June 2022 | 31 December 2022 |
| Cash and cash equivalents | 175 | 431 | 408 |
| Current interest-bearing receivables | 150 | 83 | 83 |
| Non-current interest-bearing receivables | 33 | 32 | 33 |
| Interest-bearing assets | 358 | 545 | 523 |
| Current interest-bearing leasing liabilities | | | 2 |
| Current interest-bearing leasing habilities | 2 | 2 | |
| Non-current interest-bearing leasing liabilities | 0 | 2 | 1 |
| | | | 1 3 |

Bure Equity finances operations in Atle Investment Management and Bure Growth with equity and loans. The table below presents internal loans in the Bure Group.

| | Internal receivables within the Group | | | | | |
|----------------------------|---------------------------------------|--------------|------------------|--|--|--|
| SEK M | 30 June 2023 | 30 June 2022 | 31 December 2022 | | | |
| Atle Investment Management | 149 | 81 | 81 | | | |
| Bure Growth | 486 | 449 | 449 | | | |
| Total | 635 | 530 | 531 | | | |

Note 7 - Issued securities and contingent liabilities

As of 30 June 2023, the investment entity had not posted any security and had not entered into contingent liabilities.

Definitions

Basic earnings per share

Profit/loss after tax divided by the average number of shares outstanding during the year. For the Group, net profit less the non-controlling interests' share in profit for the year.

Diluted earnings per share

Profit after tax divided by the average number of shares outstanding during the year after dilution. For the Group, net profit less non-controlling interests' share in profit for the year. The average number of shares after full dilution is calculated according to the rules in IFRS, IAS 33 Earnings per Share.

Earnings per share

Earnings after tax divided by the average number of outstanding shares during the period. For the parent company, net earnings is used less the minority share of earnings for the period.

The average number of shares after dilution is calculated according to IFRS regulation, IAS 33 Earnings per share.

EBIT

Operating profit after amortization of goodwill/ acquisition-related surplus values and amortization of fixed assets.

Equity per share

Equity divided by the number of shares outstanding. As of the transition to IFRS on 1 January 2005, non-controlling interests are included in total equity.

Equity/asset ratio

Equity in relation to total assets. As of the transition to IFRS on 1 January 2005, non-controlling interests are included in total equity.

Growth

Increase in net sales in relation to net sales for the previous year. The key figure thus includes both organic and acquisition-driven growth.

IRR

Internal Rate of Return.

Management costs/net asset value

Management costs during the period divided by net asset value at the end of the period.

Market capitalization

Share price multiplied by the total number of shares outstanding.

Net asset value

Market value, (valued at fair value), of Bure's listed and unlisted holdings and short-term investments plus accrued acquisition value of other net assets and cash and cash equivalents.

Net loan liability

Same definition as net loan receivable, but is used when interest-bearing liabilities exceed interest-bearing assets.

Net loan receivable

Financial interest-bearing assets minus interest-bearing liabilities.

Return on equity

Profit/loss after tax divided by average equity.

Share buyback

For several years, Swedish companies have been permitted to repurchase up to 10 per cent of their own outstanding shares, provided that this is approved by the Annual General Meeting within the framework of non-restricted equity.

Total return

The total of the year's share price growth and reinvested dividends divided by the share price at the beginning of the year.

This is Bure

Bure is a listed investment company that is quoted on Nasdaq Stockholm Large Cap. The portfolio consisted of eleven companies, of which seven are listed holdings.

Our business concept is to be a long-term principal owner of operating companies. Through far-reaching engagement and value-driving initiatives and activities, we support the portfolio companies in becoming successful in their respective businesses.

Our objective is to create a long-term sustainable total return for our shareholders and to be a competitive investment alternative in the market.

Bure's strategic cornerstones are:

- · Long-term approach
- · Commitment and responsibility
- · Adapted leadership
- · Financial strength

Financial calendar

Interim report January – September Year-end report 2023 9 November 202322 February 2024

For information contact

Henrik Blomquist, CEO: +46 8 614 00 20 Max Jonson, CFO: +46 8 614 00 20